TY - JOUR
AU - Miragoli, P.
AB - PharmacoEconomics - Italian Research Articles 6 (1): 15-30, 2004 1590-9158/04/0004-0015/$8.00/0 © Adis International Limited. Tutti i diritti riservati. Costi ed efficacia della cura della schizofrenia con antipsicotici tipici e atipici 1 2 3 4 5 V. Mapelli, R. Bezzi, A. Erlicher, A. Lora, P. Miragoli 1 Istituto di Economia Sanitaria, Milano 2 U.O.P Legnano, Milano 3 U.O.P Niguarda 1, Milano 4 U.O.P Desio, Milano 5 U.O.P.S. Carlo Borromeo, Milano Cost-effectiveness of treatment of schizophrenia with typical and atypical antipsychotics Summary Introduction: Schizophrenia is a ravaging and costly mental illness. Treatment of schizophrenia is long term and involves different kinds of care (drugs, outpatient, hospital, and residential care). Antipsychotic drugs contribute substantially to control patients positive and negative symptoms. In the late 90’s, new “atypical” antipsychotics have been introduced, which are supposed to be more effective, but also are more expensive. However evidence on cost- effectiveness of atypical drugs is yet limited. Objective: First, to compare effectiveness and costs of 12 month treatment of schizophrenia, using typical and atypical antipsychotics, associated with psychiatric services. Second, to compare the three most prescribed atypical drugs (olanzapine, clozapine, and risperidone) to the drug of choice, haloperidol. Patients and methods: This study originates from 
TI - Costi ed efficacia della cura della schizofrenia con antipsicotici tipici e atipici
JF - PharmacoEconomics Italian Research Articles
DO - 10.1007/BF03320619
DA - 2013-02-27
UR - https://www.deepdyve.com/lp/springer-journals/costi-ed-efficacia-della-cura-della-schizofrenia-con-antipsicotici-aE0GFl0c7B
SP - 15
EP - 30
VL - 6
IS - 1
DP - DeepDyve
ER -